Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001338892 | SCV001532597 | uncertain significance | Cohen syndrome | 2022-06-27 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with leucine, which is neutral and non-polar, at codon 2102 of the VPS13B protein (p.Arg2102Leu). This variant is present in population databases (rs747116389, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with VPS13B-related conditions. ClinVar contains an entry for this variant (Variation ID: 1035950). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Natera, |
RCV001338892 | SCV002082605 | uncertain significance | Cohen syndrome | 2020-09-27 | no assertion criteria provided | clinical testing | |
Prevention |
RCV003898320 | SCV004714412 | uncertain significance | VPS13B-related disorder | 2024-08-27 | no assertion criteria provided | clinical testing | The VPS13B c.6230G>T variant is predicted to result in the amino acid substitution p.Arg2077Leu. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.020% of alleles in individuals of Latino descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |